Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets
Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags
Key Terms
initial public offeringfinancial
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
alpha-emitting radiopharmaceuticalsmedical
Alpha-emitting radiopharmaceuticals are medicines that carry tiny, highly powerful radioactive particles directly to diseased cells—most often cancer—so the energy kills those cells while sparing nearby healthy tissue. Think of them as microscopic guided bullets that deliver a short, intense burst of energy where it’s needed. Investors care because successful drugs in this class can command premium prices and quickly change a company’s revenue and risk profile, but they also require specialized manufacturing, regulation, and distribution.
radiopharmaceuticalmedical
A radiopharmaceutical is a special type of medicine that contains a small amount of radioactive material, used primarily for medical imaging or treatment. It can be thought of as a tiny, targeted signal that helps doctors see inside the body or deliver therapy directly to affected areas. For investors, understanding radiopharmaceuticals is important because they represent a growing field within healthcare, driven by advancements in diagnostics and personalized treatments.
actinium-225medical
Actinium-225 is a rare, radioactive form of the metal actinium used as a microscopic radiation source in some cancer treatments; it emits very strong, short-range radiation that can destroy diseased cells when attached to a carrier drug. Investors pay attention because supply is limited and production is complex, so shortages or cost changes can directly affect the development, manufacturing and valuation of companies pursuing therapies that rely on this scarce medical “fuel.”
Series Afinancial
Series A is the first major round of outside equity financing for a privately held startup, where professional investors buy ownership stakes in exchange for capital to help the company move from early proof-of-concept toward scalable operations. It matters to investors because it sets an early price for the company and signals market confidence; successful Series A investments can deliver large returns if the business grows, but they also carry high risk similar to backing a promising prototype that still needs development.
Nectin-4–expressingmedical
Cells described as nectin-4–expressing produce the protein nectin-4 on their surface, which can act like a visible flag that distinguishes those cells from others. For investors, that flag matters because it creates a specific target for drugs, imaging agents, or tests: therapies designed to bind nectin-4 can home in on those cells, affecting the potential market size, clinical strategy and regulatory prospects for related medical products.
B7-H3–expressingmedical
b7-h3–expressing describes cells or tumors that produce the B7‑H3 protein (also known as CD276) on their surface, a molecule involved in immune signaling. For investors, it indicates whether a therapy or diagnostic aimed at B7‑H3 can be used in a given patient population—like knowing if a house has the right kind of electrical outlet before selling a specialty appliance—affecting the potential market size, trial design, and commercial risk.
Vida has partnered with Aktis since co-leading its Series A, supporting the company from discovery through IPO and establishing itself as one of Aktis’ largest shareholders; Helen Kim, Vida Senior Managing Director, has served on the Board since 2021
Brian Goodman, Ph.D., Managing Director at Vida Ventures and Co-Founder of Aktis, served as founding Chief Operating Officer, helping to establish the company’s early operational, scientific, and strategic foundation
LOS ANGELES & BOSTON--(BUSINESS WIRE)--
Vida Ventures (“Vida”), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for the treatment of solid tumors. Aktis raised $318 million in its initial public offering, reflecting strong investor interest, its recently announced anchor investment by Eli Lilly and Company (NYSE: LLY), and pipeline momentum as the company enters the public markets.
Vida has supported Aktis since co-leading its Series A, beginning with early platform diligence and company building efforts and continuing through multiple private financings and strategic inflection points leading up to the IPO, with Vida’s Helen Kim serving on the Aktis Board of Directors throughout this period. Vida is the second largest shareholder in the company leading up to the IPO.
“Aktis represents the type of company Vida was envisioned to build and support, grounded in differentiated science, built with operational rigor, and developed through hands-on partnership,” said Helen S. Kim, Senior Managing Director at Vida Ventures and Board Member at Aktis. “As Aktis prepares to enter the public markets, we are proud of the role we’ve played in building the company and its potential to deliver transformative therapies for patients with cancer.”
Aktis Oncology was co-founded by Brian Goodman, Ph.D., Managing Director at Vida Ventures, who served as the company’s founding Chief Operating Officer until August 2022 and later, its Chief Business Officer until May 2024. Dr. Goodman helped translate foundational science into a scalable operating company working hand in hand with the management team led by Matthew Roden, Chief Executive Officer of Aktis, establishing critical capabilities and supporting Aktis’ strategic collaboration with Eli Lilly, for a total deal valued at up to $1.2 billion.
“From the outset, our goal with Aktis was to build a company around a highly differentiated alpha-radiopharmaceutical platform based on miniproteins with the potential to meaningfully impact patients with solid tumors,” said Brian Goodman, Ph.D., Managing Director at Vida Ventures and Co-Founder of Aktis. “That required not just strong science, but thoughtful company building by assembling the right capabilities, partnerships, and culture to support long-term execution. Seeing Aktis reach the public markets is a testament to the team and to the company’s continued progress.”
Founded in 2020, Aktis Oncology is developing targeted alpha-particle therapies designed to selectively deliver potent radioactive payloads to tumor cells while minimizing damage to healthy tissue. The company had previously raised approximately $346 million in private capital and is advancing a pipeline led by AKY-1189, an actinium-225–based radiopharmaceutical targeting Nectin-4–expressing tumors, and AKY-2519, targeting B7-H3–expressing tumors.
About Vida Ventures
Vida Ventures, LLC (“Vida”), founded by Arie Belldegrun, MD, is a next-generation life sciences investment firm comprised of scientists, physicians, entrepreneurs and investors, who are passionate about building and funding breakthroughs in biomedicine. Vida’s mission is to bring science to life and advance transformative biomedical innovations that have the potential to make a meaningful difference for patients. Vida currently has approximately $1.8 billion of capital commitment from blue-chip institutional investors, including top-tier endowments and foundations, sovereign wealth funds, pensions, financial institutions, family offices, fund-of-funds, and high net worth individuals. Vida has offices in Los Angeles, Boston, New York, and Fort Worth and is focused on identifying groundbreaking science and building innovative companies that lead to new areas of drug discovery and development. For more information on Vida Ventures, please visit www.vidaventures.com, on LinkedIn or follow on X @Vida_Ventures.
